Latest Shareholder Meetings News

London City reports a record investment portfolio value of $27.3 million, buoyed by strong gains in Fiducian Group shares, while legal proceedings against Excelsior Capital and its directors continue to unfold.

Gold Road Resources has secured a crucial regulatory green light as the Foreign Investment Review Board approves Gold Fields’ acquisition scheme. The deal now moves closer to shareholder and court approvals.

Yowie Group Ltd has firmly rejected the validity of director removal and nomination notices purportedly from Keybridge Capital, while confirming its status as Keybridge’s largest creditor with over $6.6 million owed. The company also detailed a recent share placement amid ongoing regulatory scrutiny.

Midas Minerals has locked in $6.5 million through a two-tranche placement to fund its strategic acquisition and exploration of the Otavi Copper Project in Namibia, alongside advancing its broader project portfolio.

Mayne Pharma has sent out the Scheme Booklet to shareholders, marking a key step in the proposed acquisition by Cosette. The booklet includes critical details to guide shareholder decisions ahead of the upcoming Scheme Meeting.

Emu NL’s recent shareholder meeting saw all attempts to remove or elect new directors decisively rejected, reinforcing board stability as the company completes a planned capital raise.

Uvre Limited is set to acquire New Zealand gold explorer Otagold, backed by a $4 million equity raise and the appointment of mining veterans Norman Seckold and Peter Nightingale to its board.

EDU Holdings has secured ASX approval to voluntarily delist, pending shareholder consent, and announced a $12.4 million equal access share buy-back to provide liquidity options for investors.

Metals X Limited has committed $5 million to acquire a significant stake in Elementos Limited through a private placement, positioning itself as a key player in the tin development sector.

Keybridge Capital urges shareholders to take no action following an off-market takeover bid from its own subsidiary, Yowie Group, citing serious governance concerns and legal disputes.

The Reject Shop Limited has entered a recommended scheme of arrangement with Dollarama Inc., offering shareholders $6.68 cash per share, a substantial premium over recent trading prices. The Independent Expert deems the deal fair and reasonable, with a shareholder meeting set for June 23.

Mayne Pharma Group has proposed a $7.40 per share acquisition by Cosette Pharmaceuticals, with unanimous board support and a fair and reasonable opinion from an independent expert. Shareholders will vote on the scheme on June 18, 2025.